AstraZeneca PLC (AZN)vsSo-Young International Inc (SY)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
SY
So-Young International Inc
$1.94
-8.06%
HEALTHCARE · Cap: $206.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3661% more annual revenue ($62.38B vs $1.66B). AZN leads profitability with a 17.7% profit margin vs -15.6%. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
SY
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Intrinsic value data unavailable for SY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Reasonable price relative to book value
Revenue surging 45.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -17.2% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : SY
The strongest argument for SY centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SY
The primary concerns for SY are Market Cap, Return on Equity, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SY is a hypergrowth play — different risk/reward profiles.
SY carries more volatility with a beta of 2.20 — expect wider price swings.
SY is growing revenue faster at 45.6% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (68/100 vs 44/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
So-Young International Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · China
So-Young International Inc. operates an online platform for consumer health and medical aesthetic services that focuses on discretionary medical treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?